Newsbenzinga
ArriVent BioPharma Doses First Patient In Phase 1 Trial Of Dual-Target ADC ARR-002 For Ovarian And Endometrial Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…